Which has preferable valuation & earnings, NCEL or DRMA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A

Is NCEL or DRMA more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Dermata Therapeutics N/A -127.91% -105.05%

Do analysts rate AIXC or DRMA?

Dermata Therapeutics has a consensus target price of $10.00, indicating a potential upside of 687.40%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dermata Therapeutics is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, AIXC or DRMA?

Dermata Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A

Is AIXC or DRMA more profitable?

Dermata Therapeutics' return on equity of -127.91% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% Dermata Therapeutics N/A -127.91% -105.05%

Which has higher valuation & earnings, DRMA or KALA?

Dermata Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is DRMA or KALA more profitable?

Dermata Therapeutics' return on equity of -127.91% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Dermata Therapeutics N/A -127.91% -105.05% KALA BIO N/A -1,336.10% -94.85%

Is DRMA or SNTI more profitable?

Dermata Therapeutics' return on equity of -127.91% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Dermata Therapeutics N/A -127.91% -105.05% Senti Biosciences N/A -532.05% -103.35%

Which has higher valuation and earnings, ATOS or DRMA?

Atossa Genetics is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atossa Genetics N/A N/A -$34.77M -$3.21 N/A Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A

Is ATOS or DRMA more profitable?

Atossa Genetics' return on equity of -84.91% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -84.91% -72.36% Dermata Therapeutics N/A -127.91% -105.05%

Dermata Therapeutics (DRMA) Competitors

$1.27 -0.06 (-4.51%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$1.32 +0.05 (+4.02%)

As of 06:24 AM Eastern

Compare

DRMA vs. NCEL, AIXC, KALA, SNTI, and ATOS

Should you buy Dermata Therapeutics stock or one of its competitors? MarketBeat compares Dermata Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dermata Therapeutics include NLS Pharmaceutics (NCEL), Qualigen Therapeutics (AIXC), KALA BIO (KALA), Senti Biosciences (SNTI), and Atossa Genetics (ATOS). These companies are all part of the "pharmaceutical products" industry.

How does Dermata Therapeutics compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A

NLS Pharmaceutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

In the previous week, NLS Pharmaceutics' average media sentiment score of 1.00 beat Dermata Therapeutics' score of 0.00 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
NLS Pharmaceutics	Positive
Dermata Therapeutics	Neutral

NLS Pharmaceutics currently has a consensus price target of $23.00, suggesting a potential upside of 479.35%. Dermata Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 687.40%. Given Dermata Therapeutics' higher probable upside, analysts plainly believe Dermata Therapeutics is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NLS Pharmaceutics' return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Dermata Therapeutics	N/A	-127.91%	-105.05%

8.7% of Dermata Therapeutics shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

NLS Pharmaceutics and Dermata Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Dermata Therapeutics compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Qualigen Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Dermata Therapeutics' return on equity of -127.91% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Dermata Therapeutics	N/A	-127.91%	-105.05%

Dermata Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 21.9% of Dermata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Dermata Therapeutics has a consensus target price of $10.00, indicating a potential upside of 687.40%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dermata Therapeutics is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Dermata Therapeutics	Neutral

Summary

Dermata Therapeutics beats Qualigen Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Dermata Therapeutics compare to KALA BIO?

Dermata Therapeutics (NASDAQ:DRMA) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Dermata Therapeutics' return on equity of -127.91% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
KALA BIO	N/A	-1,336.10%	-94.85%

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by insiders. Comparatively, 2.2% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dermata Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 687.40%. KALA BIO has a consensus price target of $1,158.33, indicating a potential upside of 154,365.04%. Given KALA BIO's higher possible upside, analysts plainly believe KALA BIO is more favorable than Dermata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dermata Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market.

Dermata Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

In the previous week, KALA BIO had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 1 mentions for KALA BIO and 0 mentions for Dermata Therapeutics. KALA BIO's average media sentiment score of 0.98 beat Dermata Therapeutics' score of 0.00 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
KALA BIO	Positive

Summary

KALA BIO beats Dermata Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Dermata Therapeutics compare to Senti Biosciences?

Dermata Therapeutics (NASDAQ:DRMA) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Senti Biosciences had 3 more articles in the media than Dermata Therapeutics. MarketBeat recorded 3 mentions for Senti Biosciences and 0 mentions for Dermata Therapeutics. Senti Biosciences' average media sentiment score of 0.23 beat Dermata Therapeutics' score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Senti Biosciences	Neutral

Dermata Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dermata Therapeutics has higher earnings, but lower revenue than Senti Biosciences. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
Senti Biosciences	$20K	675.64	-$61.44M	-$1.92	N/A

Dermata Therapeutics' return on equity of -127.91% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
Senti Biosciences	N/A	-532.05%	-103.35%

Dermata Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 687.40%. Senti Biosciences has a consensus price target of $10.00, suggesting a potential upside of 2,205.21%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Dermata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Senti Biosciences beats Dermata Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Dermata Therapeutics compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Atossa Genetics is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A

Atossa Genetics' return on equity of -84.91% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
Dermata Therapeutics	N/A	-127.91%	-105.05%

Atossa Genetics has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

In the previous week, Atossa Genetics' average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company	Overall Sentiment
Atossa Genetics	Neutral
Dermata Therapeutics	Neutral

Atossa Genetics currently has a consensus target price of $20.33, suggesting a potential upside of 716.60%. Dermata Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 687.40%. Given Atossa Genetics' stronger consensus rating and higher possible upside, research analysts clearly believe Atossa Genetics is more favorable than Dermata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Atossa Genetics beats Dermata Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Dermata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRMA vs. The Competition

Export

Metric	Dermata Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.35M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.24	20.49	27.07	23.94
Price / Sales	N/A	300.33	512.71	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.58	7.92	10.63	6.14
Net Income	-$7.56M	$23.81M	$3.60B	$331.74M
7 Day Performance	-3.79%	-1.09%	-1.24%	-1.82%
1 Month Performance	8.55%	2.56%	1.09%	-1.45%
1 Year Performance	-81.72%	42.16%	23.66%	16.32%

Dermata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRMA Dermata Therapeutics	2.0873 of 5 stars	$1.27 -4.5%	$10.00 +687.4%	-81.2%	$5.35M	N/A	N/A	8	Gap Down
NCEL NLS Pharmaceutics	3.6494 of 5 stars	$3.83 -3.8%	$23.00 +500.5%	-82.1%	$20.49M	N/A	N/A	6	Positive News
AIXC Qualigen Therapeutics	0.1211 of 5 stars	$1.01 +2.2%	N/A	N/A	$20.48M	N/A	N/A	50
KALA KALA BIO	2.369 of 5 stars	$1.10 +14.2%	$1,158.33 +105,203.0%	-99.7%	$20.45M	N/A	N/A	30
SNTI Senti Biosciences	3.212 of 5 stars	$0.61 -36.5%	$10.00 +1,528.7%	-77.8%	$20.43M	$20K	N/A	4	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRMA) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dermata Therapeutics (DRMA) Competitors

DRMA vs. NCEL, AIXC, KALA, SNTI, and ATOS

How does Dermata Therapeutics compare to NLS Pharmaceutics?

Summary

How does Dermata Therapeutics compare to Qualigen Therapeutics?

Summary

How does Dermata Therapeutics compare to KALA BIO?

Summary

How does Dermata Therapeutics compare to Senti Biosciences?

Summary

How does Dermata Therapeutics compare to Atossa Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA vs. The Competition

Dermata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dermata Therapeutics (DRMA) Competitors

DRMA vs. NCEL, AIXC, KALA, SNTI, and ATOS

How does Dermata Therapeutics compare to NLS Pharmaceutics?

Which has preferable valuation & earnings, NCEL or DRMA?

Which has more risk and volatility, NCEL or DRMA?

Does the media favor NCEL or DRMA?

Do analysts recommend NCEL or DRMA?

Is NCEL or DRMA more profitable?

Do institutionals & insiders have more ownership in NCEL or DRMA?

Summary

How does Dermata Therapeutics compare to Qualigen Therapeutics?

Which has more volatility & risk, AIXC or DRMA?

Is AIXC or DRMA more profitable?

Which has higher earnings and valuation, AIXC or DRMA?

Do insiders & institutionals have more ownership in AIXC or DRMA?

Do analysts rate AIXC or DRMA?

Does the media favor AIXC or DRMA?

Summary

How does Dermata Therapeutics compare to KALA BIO?

Is DRMA or KALA more profitable?

Do insiders and institutionals believe in DRMA or KALA?

Do analysts prefer DRMA or KALA?

Which has more risk & volatility, DRMA or KALA?

Which has higher valuation & earnings, DRMA or KALA?

Does the media prefer DRMA or KALA?

Summary

How does Dermata Therapeutics compare to Senti Biosciences?

Does the media refer more to DRMA or SNTI?

Which has more volatility and risk, DRMA or SNTI?

Do institutionals and insiders have more ownership in DRMA or SNTI?

Which has higher earnings & valuation, DRMA or SNTI?

Is DRMA or SNTI more profitable?

Do analysts prefer DRMA or SNTI?

Summary

How does Dermata Therapeutics compare to Atossa Genetics?

Do insiders and institutionals have more ownership in ATOS or DRMA?

Which has higher valuation and earnings, ATOS or DRMA?

Is ATOS or DRMA more profitable?

Which has more risk and volatility, ATOS or DRMA?

Does the media refer more to ATOS or DRMA?

Do analysts recommend ATOS or DRMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA vs. The Competition

Dermata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools